Literature DB >> 11734238

Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis.

A De Soyza, A McDowell, L Archer, J H Dark, S J Elborn, E Mahenthiralingam, K Gould, P A Corris.   

Abstract

Burkholderia cepacia is a group of organisms that comprises seven genotypically distinct species (B cepacia genomovars I-VII), which are collectively known as the B cepacia complex. Preoperative infection with B cepacia is associated with a poor prognosis in lung transplant recipients with cystic fibrosis. Many centres do not, therefore, offer transplants to these individuals. Our aim was to ascertain whether or not post-transplant mortality is affected by pretransplant genomovar status. We studied archived isolates with PCR-based methods, and recorded excessive mortality in patients infected with B cepacia genomovar III, but not in those infected with other genomovars.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734238     DOI: 10.1016/S0140-6736(01)06808-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  26 in total

1.  Fatal outcome of lung transplantation in cystic fibrosis patients due to small-colony variants of the Burkholderia cepacia complex.

Authors:  S Häussler; C Lehmann; C Breselge; M Rohde; M Classen; B Tümmler; P Vandamme; I Steinmetz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-28       Impact factor: 3.267

2.  CD4+ T cell epitopes of FliC conserved between strains of Burkholderia: implications for vaccines against melioidosis and cepacia complex in cystic fibrosis.

Authors:  Julie A Musson; Catherine J Reynolds; Darawan Rinchai; Arnone Nithichanon; Prasong Khaenam; Emmanuel Favry; Natasha Spink; Karen K Y Chu; Anthony De Soyza; Gregory J Bancroft; Ganjana Lertmemongkolchai; Bernard Maillere; Rosemary J Boyton; Daniel M Altmann; John H Robinson
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

Review 3.  Current status of paediatric heart, lung, and heart-lung transplantation.

Authors:  M Burch; P Aurora
Journal:  Arch Dis Child       Date:  2004-04       Impact factor: 3.791

4.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

Review 5.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 6.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

7.  7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia.

Authors:  Magally Romero-Tabarez; Rolf Jansen; Marita Sylla; Heinrich Lünsdorf; Susanne Häussler; Dwi A Santosa; Kenneth N Timmis; Gabriella Molinari
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

8.  Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III.

Authors:  Tom Coenye; Theodore Spilker; Alissa Martin; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

Review 9.  Impact of multidrug-resistant organisms on patients considered for lung transplantation.

Authors:  Shmuel Shoham; Pali D Shah
Journal:  Infect Dis Clin North Am       Date:  2013-04-17       Impact factor: 5.982

Review 10.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.